Staff editor
The development of probiotics presents major regulatory challenges. We discussed it this Clara Desvignes from Voisin Consulting Life Sciences.
The gut microbiota differs between ethnic groups, a study led by Andrew Brooks at Vanderbilt University in Nashville and published in PLOS Biology claims.
MetaboGen is active in the field of live biotherapeutic products and on the study of liver diseases. We discussed their approach with Sara Malcus, CEO of the company.
New technologies such as the analysis of the "aquatic microbiota" allow to dig deeply into the microbiome chemistry. We discuss this approach with Ross Youngs, CEO of Biosortia.
Prof. Lars Engstrand from the Karolinska Institutet, in Stockholm, Sweden, explains how studying the vaginal microbiota could impact on reproductive medicine.
According to J. Kinross, from Imperial College London, there's an urgent need to understand the role of the intestinal microbiome in the etiology of cancer.
According to Prof. Ted Dinan, who has been investigating the brain-intestinal axis for years, the gut microbiota plays a role in the genesis of depression.
We discuss how microbiota could represent a resource for the development of new therapies for cancer patients with prof. Nissan Yissachar (Israel).
Antonio Gasbarrini, director of CEMAD at the Gemelli Hospital in Rome, explains how the microbiome clinics will help us against a variety of diseases.
Scott Snapper, professor at Harvard Medical School, talks about IBD and therapeutic possibilities based on the manipulation of the intestinal microbiota.
